Michael R Gold

List of Publications by Year
in descending order

181 papers	10,064 citations	53794 45 h-index	37204 96 g-index
183 all docs	183 docs citations	183 times ranked	6402 citing authors

#	Article	IF	Citations
1	Epicardial mapping and ablation of ventricular tachycardia from the coronary venous system in post-coronary bypass patients. Journal of Interventional Cardiac Electrophysiology, 2023, 66, 145-151.	1.3	7
2	European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology. Europace, 2022, 24, 165-172.	1.7	20
3	Is left bundle area pacing the future of pacing for bradycardia?. Heart Rhythm, 2022, 19, 12.	0.7	0
4	CRT Efficacy in â€œMid-Rangeâ€•QRS Duration Among Asians Contrasted to Non-Asians, and Influence of Height. JACC: Clinical Electrophysiology, 2022, 8, 211-221.	3.2	6
5	Temporal Association of Atrial Fibrillation With Cardiac Implanted Electronic Device Detected HeartÂFailure Status. JACC: Clinical Electrophysiology, 2022, 8, 182-193.	3.2	4
6	Research Opportunities in Autonomic Neural Mechanisms of CardiopulmonaryÂRegulation. JACC Basic To Translational Science, 2022, 7, 265-293.	4.1	17
7	Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke. Europace, 2022, , .	1.7	13
8	Can We Treat an Older Patient With a New Trick?. Journal of the American College of Cardiology, 2022, 79, 1060-1062.	2.8	0
9	Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation, 2021, 143, 7-17.	1.6	132
10	Metaâ€analysis comparing outcomes of catheter ablation for ventricular arrhythmia in ischemic versus nonischemic cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 54-62.	1.2	8
11	Predicting complete heart block after alcohol septal ablation for hypertrophic cardiomyopathy using a risk stratification model and clinical tool. Catheterization and Cardiovascular Interventions, 2021, 98, 393-400.	1.7	6
12	Outcomes of two versus three incision techniques: Results from the subcutaneous ICD postâ€approval study. Journal of Cardiovascular Electrophysiology, 2021, 32, 792-801.	1.7	7
13	Racial difference in atrial size and extracellular matrix homeostatic response to hypertension: Is this a potential mechanism of reduced atrial fibrillation in African Americans?. Heart Rhythm O2, 2021, 2, 37-45.	1.7	5
14	Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices. Journal of the American Heart Association, 2021, 10, e018127.	3.7	7
15	Impact of age on catheter ablation of premature ventricular contractions. Journal of Cardiovascular Electrophysiology, 2021, 32, 1077-1084.	1.7	2
16	The problematic lag between FDA approval of medical devices and CMS coverage. Journal of Cardiovascular Electrophysiology, 2021, 32, 1801-1802.	1.7	2
17	Modified design of stimulation of the left ventricular endocardium for cardiac resynchronization therapy in nonresponders, previously untreatable and high-risk upgrade patients (SOLVE-CRT) trial. American Heart Journal, 2021, 235, 158-162.	2.7	9
18	Device-Detected Atrial Fibrillation Before and After Hospitalisation for Noncardiac Surgery or Medical Illness: Insights From ASSERT. Canadian Journal of Cardiology, 2021, 37, 803-809.	1.7	6

#	Article	IF	Citations
19	Relationship of paced left bundle branch pacing morphology with anatomic location and physiological outcomes. Heart Rhythm, 2021, 18, 946-953.	0.7	21
20	The Subcutaneous ICD: A Review of the UNTOUCHED and PRAETORIAN Trials. Arrhythmia and Electrophysiology Review, 2021, 10, 108-112.	2.4	14
21	Redefining the Classifications of Response to Cardiac Resynchronization Therapy. JACC: Clinical Electrophysiology, 2021, 7, 871-880.	3.2	33
22	Electrical delays in quadripolar leads with cardiac resynchronization therapy. Journal of Cardiovascular Electrophysiology, 2021, 32, 2498-2503.	1.7	4
23	The cost of non-response to cardiac resynchronization therapy: characterizing heart failure events following cardiac resynchronization therapy. Europace, 2021, 23, 1586-1595.	1.7	10
24	Contrast-enhanced image-guided lead deployment for left bundle branch pacing. Heart Rhythm, 2021, 18, 1318-1325.	0.7	29
25	Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial. Circulation, 2021, 144, 1543-1552.	1.6	190
26	Evaluating outcomes of same-day discharge after catheter ablation for atrial fibrillation in a real-world cohort. Heart Rhythm O2, 2021, 2, 333-340.	1.7	5
27	Sameâ€day discharge after catheter ablation in patients with atrial fibrillation in a large nationwide administrative claims database. Journal of Cardiovascular Electrophysiology, 2021, 32, 2432-2440.	1.7	10
28	Estimating Left Ventricular Electrical Delay From the Right Ventricular Lead Electrogram. JACC: Clinical Electrophysiology, 2021, 7, 1195-1196.	3.2	0
29	The Importance of Early Evaluation after Cardiac Resynchronization Therapy to Redefine Response: Pooled Individual Patient Analysis from Five Prospective Studies. Heart Rhythm, 2021, , .	0.7	13
30	A Comparison of the Electrophysiological and Anatomic Characteristics of Pacing Different Branches of the Left Bundle Conduction System. Frontiers in Cardiovascular Medicine, 2021, 8, 781845.	2.4	4
31	Plasticity of left ventricular function with cardiac resynchronization therapy. Journal of Interventional Cardiac Electrophysiology, 2020, 57, 289-294.	1.3	1
32	Editorial commentary: The subcutaneous ICD: An expanding niche or the future of implantable defibrillators?. Trends in Cardiovascular Medicine, 2020, 30, 385-386.	4.9	0
33	Comparison of measures of ventricular delay on cardiac resynchronization therapy response. Heart Rhythm, 2020, 17, 615-620.	0.7	23
34	Realâ€world outcomes of ventricular tachycardia catheter ablation with versus without intracardiac echocardiography. Journal of Cardiovascular Electrophysiology, 2020, 31, 417-422.	1.7	16
35	Relationship of Shock Energy to Impedance During Subcutaneous Implantable Cardioverter-Defibrillator Testing. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008631.	4.8	4
36	Healthcare utilization and cost in patients with atrial fibrillation and heart failure undergoing catheter ablation. Journal of Cardiovascular Electrophysiology, 2020, 31, 3166-3175.	1.7	8

#	Article	IF	Citations
37	1-Year Prospective Evaluation of Clinical Outcomes and Shocks. JACC: Clinical Electrophysiology, 2020, 6, 1537-1550.	3.2	24
38	Economic implications of adding a novel algorithm to optimize cardiac resynchronization therapy: rationale and design of economic analysis for the AdaptResponse trial. Journal of Medical Economics, 2020, 23, 1401-1408.	2.1	1
39	The role of electrophysiologic study in highâ€risk patients with newâ€onset conduction disturbances following alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2020, 31, 2522-2525.	1.7	0
40	Bilateral Bundle Branch Area Pacing to Achieve Physiological Conduction System Activation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008267.	4.8	25
41	Active-Fixation Atrial Leads and the Risk of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008655.	4.8	1
42	Comparison of Left Bundle Branch and His Bundle Pacing in Bradycardia Patients. JACC: Clinical Electrophysiology, 2020, 6, 1291-1299.	3.2	64
43	Differences in clinical characteristics and reported quality of life of men and women undergoing cardiac resynchronization therapy. ESC Heart Failure, 2020, 7, 2972-2982.	3.1	9
44	Permanent His Bundle Pacing Implantation Facilitated by Visualization of the Tricuspid Valve Annulus. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008370.	4.8	19
45	Pigment nephropathy associated with percutaneous hemodynamic support during ventricular tachycardia ablation. HeartRhythm Case Reports, 2020, 6, 720-723.	0.4	2
46	Intracardiac echocardiography use and outcomes after catheter ablation of ventricular tachycardia. Journal of Comparative Effectiveness Research, 2020, 9, 375-385.	1.4	5
47	Outcomes of subcutaneous implantable cardioverter-defibrillator in dialysis patients: Results from the S-ICD post-approval study. Heart Rhythm, 2020, 17, 1566-1574.	0.7	9
48	The ECG Belt for CRT response trial: Design and clinical protocol. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 1063-1071.	1.2	7
49	Electromagnetic interference from left ventricular assist devices in patients with subcutaneous implantable cardioverterâ€defibrillators. Journal of Cardiovascular Electrophysiology, 2020, 31, 1195-1201.	1.7	20
50	Future research prioritization in cardiac resynchronization therapy. American Heart Journal, 2020, 223, 48-58.	2.7	13
51	A novel screening test for inappropriate shocks due to myopotentials from the subcutaneous implantable cardioverterâ€“defibrillator. Heart Rhythm O2, 2020, 1, 27-34.	1.7	2
52	Electrocardiogram in CardiacÂResynchronization Therapy. Journal of the American College of Cardiology, 2019, 73, 3100-3101.	2.8	0
53	The effect of posture, exercise, and atrial pacing on atrioventricular conduction in systolic heart failure. Journal of Cardiovascular Electrophysiology, 2019, 30, 2892-2899.	1.7	2
54	Evaluation, Management, and Outcomes of Patients Poorly Responsive to CardiacÂResynchronization Device Therapy. Journal of the American College of Cardiology, 2019, 74, 2588-2603.	2.8	60

#	Article	IF	Citations
55	Optimization of Cardiac Resynchronization Therapy. JACC: Clinical Electrophysiology, 2019, 5, 1026-1027.	3.2	0
56	Left bundle branch pacing for symptomatic bradycardia: Implant success rate, safety, and pacing characteristics. Heart Rhythm, 2019, 16, 1758-1765.	0.7	154
57	Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED): Clinical characteristics and perioperative results. Heart Rhythm, 2019, 16, 1636-1644.	0.7	48
58	Design and rationale for the Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in non-responders and previously untreatable patients (SOLVE-CRT) trial. American Heart Journal, 2019, 217, 13-22.	2.7	23
59	Â. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1075-1075.	1.2	0
60	Factors Associated With High-Voltage Impedance and Subcutaneous Implantable Defibrillator Ventricular Fibrillation Conversion Success. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e006665.	4.8	33
61	A Substernal Defibrillator LeadÂWithÂPacing Capability. JACC: Clinical Electrophysiology, 2019, 5, 197-198.	3.2	0
62	Prophylactic pulmonary vein isolation during cavotricuspid isthmus ablation for atrial flutter: A metaâ€analysis. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 493-498.	1.2	16
63	Left Bundle Branch Pacing. Journal of the American College of Cardiology, 2019, 74, 3039-3049.	2.8	150
64	Rationale and design for AMPLATZER Amulet Left Atrial Appendage Occluder IDE randomized controlled trial (Amulet IDE Trial). American Heart Journal, 2019, 211, 45-53.	2.7	30
65	Competitive athletes with implantable cardioverterâ€“defibrillatorsâ€”How to program? Data from the Implantable Cardioverterâ€“Defibrillator Sports Registry. Heart Rhythm, 2019, 16, 581-587.	0.7	27
66	Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial. Heart Rhythm, 2019, 16, 743-753.	0.7	11
67	Treatment of Subclinical Atrial Fibrillation. Circulation, 2018, 137, 217-218.	1.6	10
68	Use of antibiotic envelopes to prevent cardiac implantable electronic device infections: A metaâ€analysis. Journal of Cardiovascular Electrophysiology, 2018, 29, 609-615.	1.7	22
69	Computer Modeling. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006104.	4.8	1
70	The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individualâ€patient data metaâ€analysis. European Journal of Heart Failure, 2018, 20, 780-791.	7.1	81
71	Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT). American Heart Journal, 2018, 201, 160-163.	2.7	26
72	Effect of Interventricular Electrical Delay on Atrioventricular Optimization for Cardiac Resynchronization Therapy. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006055.	4.8	18

#	Article	IF	Citations
73	Complex Left Atrial Appendage Morphology Is an Independent Risk Factor for Cryptogenic Ischemic Stroke. Frontiers in Cardiovascular Medicine, 2018, 5, 131.	2.4	6
74	Anesthesia for subcutaneous implantable cardioverterâ€defibrillator implantation: Perspectives from the clinical experience of a U.S. panel of physicians. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 807-816.	1.2	35
75	The rationale and design of the SMART CRT trial. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1212-1216.	1.2	6
76	Response by Gold to Letter Regarding Article, â€œTreatment of Subclinical Atrial Fibrillation: Does One Plus One Always Equal Two?â€. Circulation, 2018, 138, 124-124.	1.6	1
77	Acute biventricular hemodynamic effects of cardiac resynchronization therapy in right bundle branch block. Heart Rhythm, 2018, 15, 1525-1532.	0.7	10
78	Progression of Device-Detected Subclinical Atrial Fibrillation and the RiskÂof Heart Failure. Journal of the American College of Cardiology, 2018, 71, 2603-2611.	2.8	91
79	Predicting cardiac resynchronization therapy outcomes: It is more than just left bundle branch block. Heart Rhythm, 2018, 15, 1673-1674.	0.7	0
80	A Survey of Current Anesthesia Trends for Electrophysiology Procedures. Anesthesia and Analgesia, 2018, 127, 46-53.	2.2	6
81	Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication. Heart Rhythm, 2017, 14, 367-375.	0.7	30
82	Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With CardiacÂResynchronization. JACC: Heart Failure, 2017, 5, 169-178.	4.1	34
83	Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results. Heart Rhythm, 2017, 14, 1456-1463.	0.7	137
84	The Role of Atrioventricular and Interventricular Optimization for Cardiac Resynchronization Therapy. Heart Failure Clinics, 2017, 13, 209-223.	2.1	11
85	The Impact of the PR Interval in PatientsÂReceiving Cardiac Resynchronization Therapy. JACC: Clinical Electrophysiology, 2017, 3, 818-826.	3.2	5
86	Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. European Heart Journal, 2017, 38, 1339-1344.	2.2	428
87	Predictors of shortâ€term clinical response to cardiac resynchronization therapy. European Journal of Heart Failure, 2017, 19, 1056-1063.	7.1	27
88	ICD Utilization. JACC: Clinical Electrophysiology, 2017, 3, 299-301.	3.2	0
89	The Design of the Understanding Outcomes with the Sâ€ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED). PACE - Pacing and Clinical Electrophysiology, 2017, 40, 1-8.	1.2	22
90	Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. JACC: Clinical Electrophysiology, 2017, 3, 1475-1483.	3.2	91

#	Article	IF	Citations
91	Treadmill exercise is good for the heart but not to prevent shocks. Heart Rhythm, 2017, 14, 1440-1441.	0.7	1
92	Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricularâ€•only pacing. European Journal of Heart Failure, 2017, 19, 950-957.	7.1	33
93	Impact of Renal Function on Survival After Cardiac Resynchronization Therapy. American Journal of Cardiology, 2017, 120, 262-266.	1.6	6
94	The role of interventricular conduction delay to predict clinical response with cardiac resynchronization therapy. Heart Rhythm, 2017, 14, 1748-1755.	0.7	37
95	Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent?. Heart Rhythm, 2017, 14, e41-e44.	0.7	91
96	Economic Value and Cost-Effectiveness ofÂCardiac Resynchronization Therapy Among Patients With Mild Heart Failure. JACC: Heart Failure, 2017, 5, 204-212.	4.1	30
97	Vagus Nerve Stimulation for the Treatment of Heart Failure. Journal of the American College of Cardiology, 2016, 68, 149-158.	2.8	283
98	Impact of magnetic resonance imaging on ventricular tachyarrhythmia sensing: Results of the Evera MRI Study. Heart Rhythm, 2016, 13, 1631-1635.	0.7	7
99	Magnetic Resonance Imaging-Conditional External Cardiac Defibrillator. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	1
100	Positive Psychotherapy to Improve Autonomic Function and Mood in ICD Patients (PAMâ€•ICD): Rationale and Design of an RCT Currently Underway. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 458-470.	1.2	57
101	The Effect of Chronic Kidney Disease on Mortality with Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 863-869.	1.2	12
102	Image Quality of Cardiac Magnetic Resonance Imaging in Patients With an Implantable Cardioverter Defibrillator System Designed for the Magnetic Resonance Imaging Environment. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	48
103	Reduced Mortality Associated WithÂQuadripolar Compared to BipolarÂLeftÂVentricular Leads in CardiacÂResynchronization Therapy. JACC: Clinical Electrophysiology, 2016, 2, 426-433.	3.2	41
104	Interventricular Electrical Delay IsÂPredictive of Response to CardiacÂResynchronizationÂTherapy. JACC: Clinical Electrophysiology, 2016, 2, 438-447.	3.2	37
105	Safety and Efficacy of the Subcutaneous Implantable Defibrillator. Journal of the American College of Cardiology, 2016, 67, 445-454.	2.8	64
106	Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. Heart Rhythm, 2016, 13, 1066-1074.	0.7	92
107	Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF). Journal of Cardiac Failure, 2015, 21, 479-488.	1.7	69
108	Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE). Journal of the American Heart Association, 2015, 4, e002054.	3.7	23

#	Article	IF	Citations
109	The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: Results of the REVERSE study. Heart Rhythm, 2015, 12, 524-530.	0.7	85
110	Preclinical evaluation of implantable cardioverter-defibrillator developed for magnetic resonance imaging use. Heart Rhythm, 2015, 12, 631-638.	0.7	17
111	A New Algorithm to Reduce Inappropriate Therapy in the Sâ€ICD System. Journal of Cardiovascular Electrophysiology, 2015, 26, 417-423.	1.7	107
112	Vagal nerve stimulation for heart failure: new pieces to the puzzle?. European Journal of Heart Failure, 2015, 17, 125-127.	7.1	9
113	Response to Letter Regarding Article â€œTemporal Relationship Between Subclinical Atrial Fibrillation and Embolic Eventsâ€• Circulation, 2015, 131, e337-8.	1.6	0
114	Full-Body MRI in Patients With an Implantable Cardioverter-Defibrillator. Journal of the American College of Cardiology, 2015, 65, 2581-2588.	2.8	75
115	The Postâ€“Myocardial Infarction Pacing Remodeling Prevention Therapy (PRomPT) Trial: Design and Rationale. Journal of Cardiac Failure, 2015, 21, 601-607.	1.7	3
116	Are Leadless Pacemakers a Niche or theÂFuture of Device Therapy?âˆ—. Journal of the American College of Cardiology, 2015, 65, 1505-1508.	2.8	14
117	Expanding the Boundaries of Heart Failure Care with Interventional and Device Therapy. Heart Failure Clinics, 2015, 11, xiii.	2.1	1
118	Clinical experience with subcutaneous implantable cardioverter-defibrillators. Nature Reviews Cardiology, 2015, 12, 398-405.	13.7	14
119	Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator. Journal of the American College of Cardiology, 2015, 65, 1605-1615.	2.8	458
120	Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. European Heart Journal, 2015, 36, 2780-2789.	2.2	55
121	Novel measure of electrical dyssynchrony predicts response in cardiac resynchronization therapy: Results from the SMART-AV Trial. Heart Rhythm, 2015, 12, 2402-2410.	0.7	39
122	The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients With Heart Failure. American Journal of Cardiology, 2015, 116, S1-S9.	1.6	6
123	Biventricular Pacemaker/Defibrillators Versus Biventricular Pacemakers in Patients with Non-ischemic Cardiomyopathy. Cardiac Electrophysiology Clinics, 2015, 7, 455-459.	1.7	2
124	Long-Term Extrapolation of ClinicalÂBenefits Among Patients WithÂMildÂHeartÂFailure Receiving CardiacÂResynchronization Therapy. JACC: Heart Failure, 2015, 3, 691-700.	4.1	10
125	The Role of Atrioventricular and Interventricular Optimization for Cardiac Resynchronization Therapy. Cardiac Electrophysiology Clinics, 2015, 7, 765-779.	1.7	3
126	Developments in Cardiac Resynchronisation Therapy. Arrhythmia and Electrophysiology Review, 2015, 04, 122.	2.4	7

#	Article	IF	Citations
127	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. Circulation, 2014, 130, 94-125.	1.6	102
128	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. Heart Rhythm, 2014, 11, 1270-1303.	0.7	16
129	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. Journal of the American College of Cardiology, 2014, 64, 1143-1177.	2.8	118
130	Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events. Circulation, 2014, 129, 2094-2099.	1.6	579
131	The Effect of Left Ventricular Electrical Delay on the Acute Hemodynamic Response with Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2014, 25, 624-630.	1.7	27
132	Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm, 2014, 11, 1352-1358.	0.7	86
133	Newer Indications for ICD and CRT. Cardiology Clinics, 2014, 32, 181-190.	2.2	7
134	Update on Cardiac Resynchronisation Therapy for Heart Failure. European Cardiology Review, 2014, 9, 100.	2.2	0
135	The role of AV and VV optimization for CRT. Journal of Arrhythmia, 2013, 29, 153-161.	1.2	29
136	Comparison of Fixed Tilt and Tuned Defibrillation Waveforms: The PROMISE Study. Journal of Cardiovascular Electrophysiology, 2013, 24, 323-327.	1.7	13
137	An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. European Heart Journal, 2013, 34, 3547-3556.	2.2	410
138	The effect of left ventricular electrical delay on AV optimization for cardiac resynchronization therapy. Heart Rhythm, 2013, 10, 988-993.	0.7	38
139	Who Should Receive the Subcutaneous Implanted Defibrillator?. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 1236-1245.	4.8	40
140	Safety and Efficacy of a Totally Subcutaneous Implantable-Cardioverter Defibrillator. Circulation, 2013, 128, 944-953.	1.6	486
141	Implantable Defibrillators Improve Survival in Patients With Mildly Symptomatic Heart Failure Receiving Cardiac Resynchronization Therapy. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 1163-1168.	4.8	51
142	Effect of QRS Duration and Morphology on Cardiac Resynchronization Therapy Outcomes in Mild Heart Failure. Circulation, 2012, 126, 822-829.	1.6	279
143	Sites of left and right ventricular lead implantation and response to cardiac resynchronization therapy observations from the REVERSE trial. European Heart Journal, 2012, 33, 2662-2671.	2.2	152
144	Interactions between a Left Ventricular Assist Device and Implantable Cardioverterâ€Defibrillator. PACE - Pacing and Clinical Electrophysiology, 2012, 35, e272-3.	1.2	19

#	Article	IF	Citations
145	2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm, 2012, 9, 1524-1576.	0.7	300
146	The Subcutaneous Defibrillator. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 550-557.	0.9	7
147	Prospective comparison of discrimination algorithms to prevent inappropriate ICD therapy: Primary results of the Rhythm ID Going Head to Head Trial. Heart Rhythm, 2012, 9, 370-377.	0.7	55
148	Acute Performance of a Right Ventricular Automatic Pacing Threshold Algorithm for Implantable Defibrillators. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 259-268.	1.2	2
149	Headâ€Toâ€Head Comparison of Arrhythmia Discrimination Performance of Subcutaneous and Transvenous ICD Arrhythmia Detection Algorithms: The START Study. Journal of Cardiovascular Electrophysiology, 2012, 23, 359-366.	1.7	192
150	Atrial Support Pacing in Heart Failure: Results from the Multicenter PEGASUS CRT Trial. Journal of Cardiovascular Electrophysiology, 2012, 23, 1317-1325.	1.7	39
151	A prospective, randomized comparison of the acute hemodynamic effects of biventricular and left ventricular pacing with cardiac resynchronization therapy. Heart Rhythm, 2011, 8, 685-691.	0.7	19
152	Economic Implications and Cost-effectiveness of Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy. Heart Failure Clinics, 2011, 7, 241-250.	2.1	5
153	Temporal stability of defibrillation thresholds with cardiac resynchronization therapy. Heart Rhythm, 2011, 8, 1008-1013.	0.7	3
154	The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. Heart Rhythm, 2011, 8, 679-684.	0.7	106
155	The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. European Heart Journal, 2011, 32, 2516-2524.	2.2	305
156	Cardiac Resynchronization Therapy in Mild Heart Failure: A Review of the REVERSE and MADIT-CRT Trials. Current Cardiology Reports, 2010, 12, 367-373.	2.9	10
157	Primary Results From the SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy (SMART-AV) Trial. Circulation, 2010, 122, 2660-2668.	1.6	366
158	Response to Letters Regarding Article, â€œRole of Microvolt T-Wave Alternans in Assessment of Arrhythmia Vulnerability Among Patients With Heart Failure and Systolic Dysfunction: Primary Results From the T-Wave Alternans Sudden Cardiac Death in Heart Failure Trial Substudyâ€• Circulation, 2009, 120, .	1.6	1
159	Role of cardiac resynchronization therapy in asymptomatic and mildly symptomatic heart failure. Current Heart Failure Reports, 2009, 6, 44-48.	3.3	1
160	Defibrillation Testing at ICD Implantation: Are We Asking the Wrong Question?. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 567-569.	1.2	13
161	Acute Hemodynamic Effects of Atrial Pacing with Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2009, 20, 894-900.	1.7	24
162	Impact of atrial prevention pacing on atrial fibrillation burden: Primary results of the Study of Atrial Fibrillation Reduction (SAFARI) trial. Heart Rhythm, 2009, 6, 295-301.	0.7	57

#	Article	IF	Citations
163	Randomized Trial of Cardiac Resynchronization in Mildly Symptomatic Heart Failure Patients and in Asymptomatic Patients With Left Ventricular Dysfunction and Previous Heart Failure Symptoms. Journal of the American College of Cardiology, 2008, 52, 1834-1843.	2.8	1,060
164	Optimization of superior vena cava coil position and usage for transvenous defibrillation. Heart Rhythm, 2008, 5, 394-399.	0.7	34
165	Use of Traditional and Biventricular Implantable Cardiac Devices for Primary and Secondary Prevention of Sudden Death. Cardiology Clinics, 2008, 26, 419-431.	2.2	5
166	Role of Microvolt T-Wave Alternans in Assessment of Arrhythmia Vulnerability Among Patients With Heart Failure and Systolic Dysfunction. Circulation, 2008, 118, 2022-2028.	1.6	174
167	Sudden cardiac death: The role of risk stratification. American Heart Journal, 2007, 153, 25-33.	2.7	31
168	A Prospective Comparison of AV Delay Programming Methods for Hemodynamic Optimization during Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2007, 18, 490-496.	1.7	99
169	Comparison of Defibrillation Efficacy and Survival Associated With Right Versus Left Pectoral Placement for Implantable Defibrillators. American Journal of Cardiology, 2007, 100, 243-246.	1.6	40
170	Rationale and design of a randomized clinical trial to assess the role of overdrive and triggered prevention pacing therapies in reducing atrial fibrillation: The Study of Atrial Fibrillation Reduction (SAFARI). American Heart Journal, 2006, 152, 231-236.	2.7	10
171	Complications associated with implantable cardioverter defibrillator replacements associated with recalls. Current Cardiology Reports, 2006, 8, 313-313.	2.9	0
172	Catheter ablation for chronic atrial fibrillation. Current Cardiology Reports, 2006, 8, 313-314.	2.9	0
173	Cardiac resynchronization therapy for heart failure. Current Cardiology Reports, 2006, 8, 314-315.	2.9	1
174	Comparison of stimulation sites within left ventricular veins on the acute hemodynamic effects of cardiac resynchronization therapy. Heart Rhythm, 2005, 2, 376-381.	0.7	93
175	Effectiveness of Rapid Atrial Pacing for Termination of Drug Refractory Atrial Fibrillation: Results of a Dual Chamber Implantable Cardioverter Defibrillator Trial. Journal of Interventional Cardiac Electrophysiology, 2003, 7, 341-344.	1.0	2
176	Safety of a Single Successful Conversion of Ventricular Fibrillation Before the Implantation of Cardioverter Defibrillators. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 483-486.	1.2	32
177	T wave alternans for ventricular arrhythmia risk stratification. Current Opinion in Cardiology, 2003, 18, 1-5.	1.8	7
178	Efficacy and Temporal Stability of Reduced Safety Margins for Ventricular Defibrillation. Circulation, 2002, 105, 2043-2048.	1.6	129
179	Lack of Benefit of an Active Pectoral Pulse Generator on Atrial Defibrillation Thresholds. Journal of Cardiovascular Electrophysiology, 2002, 13, 332-335.	1.7	4
180	Advanced Rhythm Discrimination for Implantable Cardioverter Defibrillators Using Electrogram Vector Timing and Correlation. Journal of Cardiovascular Electrophysiology, 2002, 13, 1092-1097.	1.7	60

#	Article	IF	Citations
181	The Role of Subcutaneous ICDs in the Prevention of Sudden Cardiac Death. US Cardiology Review, 0, 15, .	0.5	0